| Xadago 100 mg Film-coated tablet EU/1/14/984/006-010 |
Safinamide methanesulfonate |
Zambon S.p.A. |
— |
| Xadago 50 mg Film-coated tablet EU/1/14/984/001-005 |
Safinamide methanesulfonate |
Zambon S.p.A. |
— |
| Xagrid 0.5 mg hard capsules EU/1/04/295/001 |
Anagrelide hydrochloride |
Takeda Pharmaceuticals International AG Ireland Branch |
— |
| Xalacom 50 micrograms/ml + 5 mg/ml, eye drops, solution PPA0465/406/001 |
Latanoprost, Timolol |
PCO Manufacturing Ltd. |
— |
| Xalacom 50 micrograms/mL + 5 mg/mL, eye drops, solution PA23355/056/001 |
Latanoprost, Timolol |
Viatris Healthcare Limited |
Marketed |
| Xalatan 50 micrograms/mL Eye drops, solution PA23355/057/001 |
Latanoprost |
Viatris Healthcare Limited |
Marketed |
| Xalatan 50 micrograms/mL Eye drops, solution PPA0465/520/001 |
Latanoprost |
PCO Manufacturing Ltd. |
— |
| XALKORI 20 mg granules in capsules for opening EU/1/12/793/005 |
Crizotinib |
Pfizer Europe MA EEIG |
— |
| XALKORI 200 mg hard capsules EU/1/12/793/001-002 |
Crizotinib |
Pfizer Europe MA EEIG |
— |
| XALKORI 250 mg hard capsules EU/1/12/793/003-004 |
Crizotinib |
Pfizer Europe MA EEIG |
— |
| Xaluprine 20 mg/ml oral suspension EU/1/11/727/001 |
Mercaptopurine monohydrate |
Lipomed GmbH |
— |
| Xamiol 50 micrograms/g + 0.5 mg/g gel PA1025/003/001 |
Calcipotriol, Betamethasone |
LEO Pharma A/S |
Not marketed |
| Xanax 1 mg Tablets PA23355/058/001 |
Alprazolam |
Viatris Healthcare Limited |
Marketed |
| Xanax 250 microgram Tablets PA23355/058/002 |
Alprazolam |
Viatris Healthcare Limited |
Marketed |
| Xanax 500 microgram Tablets PA23355/058/003 |
Alprazolam |
Viatris Healthcare Limited |
Marketed |
| Xarelto 1 mg/ml granules for oral suspension EU/1/08/472/050-051 |
Rivaroxaban |
Bayer AG |
— |
| Xarelto 10 mg film-coated tablets EU/1/08/472/1-8 |
Rivaroxaban |
Bayer AG |
— |
| Xarelto 15 mg film-coated tablets EU/1/08/472/011-016 |
Rivaroxaban |
Bayer AG |
— |
| Xarelto 15 mg film-coated tablets Xarelto 20 mg film-coated tablets EU/1/08/472/040 |
Rivaroxaban, Rivaroxaban |
Bayer AG |
— |
| Xarelto 2.5 mg film-coated tablets EU/1/08/472/025-033 |
Rivaroxaban |
Bayer AG |
— |
| Xarelto 20 mg film-coated tablets EU/1/08/472/017-021 |
Rivaroxaban |
Bayer AG |
— |
| Xatger 10mg prolonged release tablets PA23266/039/001 |
Alfuzosin hydrochloride |
Viatris Limited |
Marketed |
| Xatral 10mg Prolonged Release Tablets PA0540/162/003 |
Alfuzosin hydrochloride |
Sanofi-Aventis Ireland Limited T/A SANOFI |
Marketed |
| Xbryk 120 mg solution for injection EU/1/24/1889/001-002 |
Denosumab |
Samsung Bioepis NL B.V. |
— |
| Xelevia 100 mg film-coated tablets EU/1/07/382/13-18 |
Sitagliptin phosphate monohydrate |
Merck Sharp & Dohme BV |
— |
| Xelevia 25 mg film-coated tablets EU/1/07/382/1-6 |
Sitagliptin phosphate monohydrate |
Merck Sharp & Dohme BV |
— |
| Xelevia 50 mg film-coated tablets EU/1/07/382/7-12 |
Sitagliptin phosphate monohydrate |
Merck Sharp & Dohme BV |
— |
| XELJANZ 1 mg/mL oral solution EU/1/17/1178/015 |
TOFACITINIB |
Pfizer Europe MA EEIG |
— |
| XELJANZ 10 mg film-coated tablets EU/1/17/1178/005-009 |
Tofacitinib citrate |
Pfizer Europe MA EEIG |
— |
| XELJANZ 11 mg film-coated tablets EU/1/17/1178/010-013 |
TOFACITINIB |
Pfizer Europe MA EEIG |
— |
| XELJANZ 5 mg film-coated tablets EU/1/17/1178/001-003 |
Tofacitinib citrate |
Pfizer Europe MA EEIG |
— |
| Xeloda 150 mg film-coated tablets EU/1/00/163/001 |
Capecitabine |
Cheplapharm Arzneimittel GmbH |
— |
| Xeloda 500 mg film-coated tablets EU/1/00/163/002 |
Capecitabine |
Cheplapharm Arzneimittel GmbH |
— |
| Xenetix 250mg I/ml Solution for Injection PA0686/002/001 |
Iobitridol |
Guerbet |
Not marketed |
| Xenetix 300mg I/ml Solution for Injection PA0686/002/002 |
Iobitridol |
Guerbet |
Not marketed |
| Xenetix 300mg I/ml Solution for injection, polypropylene bag PA0686/002/004 |
Iobitridol |
Guerbet |
Not marketed |
| Xenetix 350mg I/ml Solution for Injection PA0686/002/003 |
Iobitridol |
Guerbet |
Not marketed |
| Xenetix 350mg I/ml Solution for injection, polypropylene bag PA0686/002/005 |
Iobitridol |
Guerbet |
Not marketed |
| Xenical 120 mg hard capsules EU/1/98/071/001 |
Orlistat |
Cheplapharm Arzneimittel GmbH |
— |
| Xenical 120 mg hard capsules EU/1/98/071/002 |
Orlistat |
CHEPLAPHARM Arzneimittel GmbH |
— |
| Xenical 120 mg hard capsules EU/1/98/071/003 |
Orlistat |
Cheplapharm Arzneimittel GmbH |
— |
| Xenical 120 mg hard capsules EU/1/98/071/004 |
Orlistat |
Cheplapharm Arzneimittel GmbH |
— |
| Xenical 120 mg hard capsules EU/1/98/071/005 |
Orlistat |
Cheplapharm Arzneimittel GmbH |
— |
| Xenical 120 mg hard capsules EU/1/98/071/006 |
Orlistat |
Cheplapharm Arzneimittel GmbH |
— |
| Xenleta 150 mg concentrate for solution for infusion EU/1/20/1457/001 |
Lefamulin |
Nabriva Therapeutics Ireland Designated Activity Company |
— |
| Xenleta 600 mg film-coated tablets EU/1/20/1457/002 |
Lefamulin |
Nabriva Therapeutics Ireland Designated Activity Company |
— |
| Xenpozyme 20 mg powder for concentrate for solution for infusion EU/1/22/1659/001-004 |
Olipudase Alfa |
Sanofi B.V. |
— |
| XEOMIN 100 units powder for solution for injection PA1907/001/002 |
Clostridium botulinum neuro-toxin type a (150 kd), free from complexing proteins |
Merz Pharmaceuticals GmbH |
Marketed |
| XEOMIN 200 units powder for solution for injection PA1907/001/003 |
Clostridium botulinum neuro-toxin type a (150 kd), free from complexing proteins |
Merz Pharmaceuticals GmbH |
Marketed |
| XEOMIN 50 units powder for solution for injection PA1907/001/001 |
Clostridium botulinum neuro-toxin type a (150 kd), free from complexing proteins |
Merz Pharmaceuticals GmbH |
Marketed |